Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging.
- Citation:
- 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors vol 13 (suppl 3) 138
- Meeting Instance:
- SNO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 1040
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- T. J. Kaufmann S. K. Anderson K. A. Jaeckle J. H. Uhm D. W. Northfelt P. J. Flynn J. C. Buckner E. Galanis
- Networks:
- Study
- NCCTG-N0776
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: